- Report
- September 2025
- 250 Pages
Global
From €3941EUR$4,490USD£3,429GBP
- Report
- September 2025
- 250 Pages
Global
From €3941EUR$4,490USD£3,429GBP
- Report
- September 2025
- 250 Pages
Global
From €3941EUR$4,490USD£3,429GBP
- Report
- June 2025
- 150 Pages
Global
From €3292EUR$3,750USD£2,864GBP
- Report
- June 2025
- 400 Pages
Global
From €4344EUR$4,949USD£3,779GBP
- Drug Pipelines
- August 2024
- 150 Pages
Global
From €3292EUR$3,750USD£2,864GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3292EUR$3,750USD£2,864GBP
- Report
- April 2023
- 117 Pages
Global
From €4169EUR$4,750USD£3,627GBP
- Report
- March 2024
- 200 Pages
Global
From €3643EUR$4,150USD£3,169GBP
- Report
- January 2024
- 156 Pages
United States
€3336EUR$3,800USD£2,902GBP
- Report
- January 2024
- 114 Pages
United States
€3072EUR$3,500USD£2,673GBP
Symbicort is a combination medication used to treat asthma and chronic obstructive pulmonary disease (COPD). It contains two active ingredients: budesonide, a corticosteroid, and formoterol, a long-acting beta-agonist. Symbicort is used to reduce inflammation and open up the airways in the lungs, allowing for easier breathing. It is available in both an inhaler and a dry powder inhaler.
Symbicort is part of a larger class of respiratory drugs known as bronchodilators. These drugs are used to treat a variety of respiratory conditions, including asthma, COPD, and bronchitis. Other bronchodilators include albuterol, salmeterol, and ipratropium.
Symbicort is manufactured by AstraZeneca, a British-Swedish pharmaceutical company. Other companies that produce similar medications include GlaxoSmithKline, Boehringer Ingelheim, and Merck. Show Less Read more